TDOC

We rate Teladoc Health, Inc. (TDOC) as Avoid with a composite score of 37.1/100 at a current price of $4.60. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.

The rating is primarily driven by strength in value (49th percentile) and quality (45th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (20th percentile) and investment (33th percentile) tempers our overall conviction. We assign a No Moat rating (30/100), Very High uncertainty, and Poor capital allocation.

Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.

Teladoc Health, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.1/100 places it at rank #3896 in our full 7,333-stock universe. At $1.4B in market capitalization, Teladoc Health, Inc. is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.

Revenue contraction of -2% combined with momentum at the 20th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.

The margin cascade tells an important story: gross margins of 70% (+10.4pp vs sector) narrow to operating margins of -11% (-14.3pp vs sector) and net margins of -8.3%, yielding a gross-to-net conversion rate of -12%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.

At a current price of $4.60, Teladoc Health, Inc. is trading near fair value based on current fundamentals. Our value factor score of 49/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.

The stock currently trades at EV/EBITDA of 8.7x (discounted to peers), P/B of 0.6x, P/S of 0.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.

We assign a Very High uncertainty rating to Teladoc Health, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.43), significant leverage (107% debt-to-equity), current negative profitability (net margin -8.3%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.

Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.43); significant leverage (107% debt-to-equity); current negative profitability (net margin -8.3%); the combination of leverage (107% D/E) and thin margins (-8.3% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 45th percentile and quality factor at the 45th percentile provide a quantitative summary of the overall risk landscape.

Key risk mitigants include: healthy gross margins of 70% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.

We rate Teladoc Health, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-15.0%), negative profitability, weak asset returns (ROA -7.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Teladoc Health, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.

Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.

In summary, Teladoc Health, Inc. receives a Avoid rating with a composite score of 37.1/100 (rank #3896 of 7,333). Our quantitative framework assigns a No Moat (30/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 38/100.

Our analysis does not support a constructive view on Teladoc Health, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.